mrna-1010
Vaccineexperimental
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
11
Phase 3
4
Phase 4
0
Earliest trial started Jul 6, 2021 (NCT04956575)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06602024 | Phase 3 | Sep 16, 2024 | Moderna Therapeutics |
| NCT05868382 | Phase 2 | May 15, 2023 | Moderna Therapeutics |
| NCT05827978 | Phase 3 | Apr 17, 2023 | Moderna Therapeutics |
| NCT05827926 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2023 | Moderna Therapeutics |
| NCT05827068 | Phase 1/Phase 2 (Phase 2) | Mar 27, 2023 | Moderna Therapeutics |
| NCT05606965 | Phase 2 | Nov 2, 2022 | Moderna Therapeutics |
| NCT05585632 | Phase 1 | Oct 14, 2022 | Moderna Therapeutics |
| NCT05566639 | Phase 3 | Sep 14, 2022 | Moderna Therapeutics |
| NCT05415462 | Phase 3 | Jun 6, 2022 | Moderna Therapeutics |
| NCT05397223 | Phase 1 | May 24, 2022 | Moderna Therapeutics |
| NCT05375838 | Phase 1/Phase 2 (Phase 2) | May 13, 2022 | Moderna Therapeutics |
| NCT05333289 | Phase 1/Phase 2 (Phase 2) | Apr 6, 2022 | Moderna Therapeutics |
| NCT04956575 | Phase 1/Phase 2 (Phase 2) | Jul 6, 2021 | Moderna Therapeutics |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Moderna Therapeutics | For profit | 13 | 13 | 3 | 2021 |
1 organizations
Page 1 / 1